Company / Depreciation & Amortization
ALNYLAM PHARMACEUTICALS, INC. Depreciation & Amortization History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$30.2M
FY2022
5-year range
$16.6M / $30.2M
FY2018-FY2022
Trend
+81.9%
vs FY2021
Sector context
#38 of 163
Health Care
What the data says
ALNYLAM PHARMACEUTICALS, INC.'s depreciation & amortization of $30M is higher than 77% of companies in the Health Care sector (FY2022). Depreciation & Amortization has increased for 4 consecutive years, from $10M in FY2018 to $30M in FY2022.
Based on SEC 10-K filings.
$30M in FY2022 with a 5-year CAGR of +20.5%. Top quartile in the Health Care sector.
Increased from $13M to $30M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +36.4%
- 5-Year CAGR
- +20.5%
- 10-Year CAGR
- -
Sector benchmark
-86.2% below sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s depreciation & amortization has grown for 4 consecutive years.
- 5-year CAGR of +20.5%, indicating consistent growth.
- In FY2022, depreciation & amortization increased 81.9% year-over-year.
- Ranks #38 out of 163 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $30.2M | +81.9% |
| FY2021 | $16.6M | +29.7% |
| FY2020 | $12.8M | +7.6% |
| FY2019 | $11.9M | +24.0% |
| FY2018 | $9.6M | -19.3% |
| FY2017 | $11.9M | +24.0% |
| FY2016 | $9.6M | -49.6% |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026